LitAlert ~~ GeneLit.com

    • Inactivation of the prolyl isomerase Pin1 sensitizes BRCA1-proficient breast cancer to PARP inhibition.
    • Luo ML, Zheng F, Chen W, Liang ZM, Chandramouly G, Tan J, Willis NA, Chen CH, de Oliveira Taveira M, Zhou XZ, Lu KP, Scully R, Wulf GM, Hu H.
    • Cancer Res. 2020 Mar 19. pii: canres.1991.2019. doi: 10.1158/0008-5472.CAN-19-2739. [Epub ahead of print]
    • An interesting case of likely BRCA2 related bilateral breast cancer with metastasis in the fimbrial part of fallopian tube.
    • Boltežar L, Gašljevic G, Novakovic S, Stegel V, Škof E.
    • Hered Cancer Clin Pract. 2020 Mar 19;18:7. doi: 10.1186/s13053-020-00139-w. eCollection 2020.
    • Short-Term Outcomes of Active Surveillance for Low-Risk Prostate Cancer Among Men with Germline DNA Repair Gene Mutations.
    • Halstuch D, Ber Y, Kedar D, Golan S, Baniel J, Margel D.
    • J Urol. 2020 Mar 19:101097JU0000000000001027. doi: 10.1097/JU.0000000000001027. [Epub ahead of print]
    • Prognostic Value of Germline DNA Repair Gene Mutations in De Novo Metastatic and Castration-Sensitive Prostate Cancer.
    • Wei Y, Wu J, Gu W, Wang J, Lin G, Qin X, Dai B, Gan H, Ye D, Zhu Y.
    • Oncologist. 2020 Mar 19. doi: 10.1634/theoncologist.2019-0495. [Epub ahead of print]
    • Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series.
    • Ni J, Zhou R, Cheng X, Xu X, Guo W, Chen X.
    • J Ovarian Res. 2020 Mar 17;13(1):29. doi: 10.1186/s13048-020-00629-4.
    • ATM-Deficient Cancers Provide New Opportunities for Precision Oncology.
    • Jette NR, Kumar M, Radhamani S, Arthur G, Goutam S, Yip S, Kolinsky M, Williams GJ, Bose P, Lees-Miller SP.
    • Cancers (Basel). 2020 Mar 14;12(3). pii: E687. doi: 10.3390/cancers12030687.
    • Therapeutic options for mucinous ovarian carcinoma.
    • Gorringe KL, Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K, Amarasinghe KC, Ananda S, Bowtell DDL, Christie M, Chiew YE, Churchman M, DeFazio A, Fereday S, Gilks CB, Gourley C, Hadley AM, Hendley J, Hunter SM, Kaufmann SH, Kennedy CJ, Köbel M, Le Page C, Li J, Lupat R, McNally OM, McAlpine JN, Pyman J, Rowley SM, Salazar C, Saunders H, Semple T, Stephens AN, Thio N, Torres MC, Traficante N, Zethoven M, Antill YC, Campbell IG, Scott CL.
    • Gynecol Oncol. 2020 Mar;156(3):552-560. doi: 10.1016/j.ygyno.2019.12.015. Epub 2020 Jan 2.
    • [PARP INHIBITORS FOR ADJUVANT TREATMENT FOR OVARIAN CANCER].
    • Marom I, Lavie O, Ostrovsky L, Kugelman N, Schmidt M, Segev Y.
    • Harefuah. 2020 Mar;159(3):175-180.
    • Review, [Article in Hebrew]
    • Molecular Mechanisms of PALB2 Function and Its Role in Breast Cancer Management.
    • Wu S, Zhou J, Zhang K, Chen H, Luo M, Lu Y, Sun Y, Chen Y.
    • Front Oncol. 2020 Feb 28;10:301. doi: 10.3389/fonc.2020.00301. eCollection 2020.